Coenzyme Q10 and statins: biochemical and clinical implications.
Level 5 - mechanism / opinion, no new human data
Narrative review of biochemical mechanisms and clinical literature without systematic review methodology
PubMed 17482884 · doi:10.1016/j.mito.2007.03.002
What was done
Narrative review synthesizing biochemical pathways and clinical literature regarding the impact of HMG-CoA reductase inhibitors (statins) on Coenzyme Q10 (CoQ10/ubiquinone) levels and associated skeletal muscle and myocardial effects.
What was found
The abstract reports no quantitative values or statistical effect sizes. It reports that statins reduce CoQ10 concentrations in plasma, platelets, and lymphocytes, with some evidence indicating decreases in skeletal muscle ubiquinone. It also notes that CoQ10 depletion during statin therapy has been reported in association with subclinical cardiomyopathy, which reversed following CoQ10 supplementation.
Why it matters
Highlights the mechanistic basis by which statin therapy disrupts endogenous CoQ10 synthesis, providing a biological rationale for statin-associated myopathy and potential bioenergetic deficits.
Limits
This is an unsystematic narrative review providing no primary experimental data, study counts, or quantitative metrics in the abstract. The clinical significance of CoQ10 depletion and the therapeutic benefit of supplementation remain speculative pending large-scale randomized controlled trials.
Cited by
- supports Statin medications block and deplete coenzyme Q10 in the body.